| scholarly article | Q13442814 |
| P356 | DOI | 10.1593/NEO.13282 |
| P8608 | Fatcat ID | release_o2ltap6oprfg7fv2rpbdma4gqe |
| P932 | PMC publication ID | 3638351 |
| P698 | PubMed publication ID | 23633920 |
| P5875 | ResearchGate publication ID | 236600530 |
| P2093 | author name string | Chinthalapally V Rao | |
| Vernon E Steele | |||
| Altaf Mohammed | |||
| Misty Brewer | |||
| Naveena B Janakiram | |||
| Krishna Vedala | |||
| P2860 | cites work | Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors | Q28193289 |
| Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats | Q28196602 | ||
| Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer | Q28218034 | ||
| Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac | Q28373322 | ||
| The development of duodenal microadenomas in FAP patients: the human correlate of the Min mouse | Q28507304 | ||
| The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators | Q29547887 | ||
| A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse | Q29616489 | ||
| Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial | Q30497323 | ||
| Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse | Q33979359 | ||
| The anti-inflammatory effect of exercise | Q34403605 | ||
| Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. | Q34528550 | ||
| Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system | Q35128757 | ||
| Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/β-catenin/cyclin D1 signaling pathway in rats | Q35522954 | ||
| Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention | Q35597223 | ||
| Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apc(Min/+) mice | Q35836055 | ||
| Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1beta | Q36620509 | ||
| Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial | Q36924101 | ||
| beta-Catenin signaling in biological control and cancer. | Q36939963 | ||
| Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation | Q37152797 | ||
| Cytokines: from gut inflammation to colorectal cancer | Q37160690 | ||
| Combination chemoprevention: future direction of colorectal cancer prevention | Q37997908 | ||
| Combination cancer therapy: Presidential address | Q39868116 | ||
| Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis | Q40330909 | ||
| Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy | Q40336868 | ||
| Role of polyamines in arginine-dependent colon carcinogenesis in Apc(Min) (/+) mice | Q42495498 | ||
| Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck | Q42644659 | ||
| Chemoprevention of colon cancer by a glutathione conjugate of 1,4-phenylenebis(methylene)selenocyanate, a novel organoselenium compound with low toxicity. | Q43590564 | ||
| Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53 | Q44590614 | ||
| Irreversible ototoxicity associated with difluoromethylornithine. | Q44973078 | ||
| Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis | Q45329573 | ||
| Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival. | Q46019480 | ||
| Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model | Q46643584 | ||
| Design considerations for efficient prostate cancer chemoprevention trials. | Q50673321 | ||
| Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. | Q53343841 | ||
| Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. | Q53413758 | ||
| Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. | Q53437653 | ||
| Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. | Q53452219 | ||
| Colon cancer: preventive agents and the present status of chemoprevention | Q54172424 | ||
| Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil | Q70316865 | ||
| Combination chemoprevention of cancer | Q71373151 | ||
| Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study | Q71664201 | ||
| Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis | Q72783362 | ||
| Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice | Q73250147 | ||
| Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos | Q73679026 | ||
| Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon | Q77221063 | ||
| APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse | Q78198375 | ||
| Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I--an independent prognostic factor | Q80352376 | ||
| P433 | issue | 5 | |
| P921 | main subject | carcinogenesis | Q1637543 |
| P304 | page(s) | 481-490 | |
| P577 | publication date | 2013-05-01 | |
| P1433 | published in | Neoplasia | Q2962042 |
| P1476 | title | Multitargeted low-dose GLAD combination chemoprevention: a novel and promising approach to combat colon carcinogenesis | |
| P478 | volume | 15 |
| Q50333246 | Cancer Chemoprevention and Piperine: Molecular Mechanisms and Therapeutic Opportunities |
| Q90290673 | Cancer Chemoprevention: Preclinical In Vivo Alternate Dosing Strategies to Reduce Drug Toxicities |
| Q28080472 | Cancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approaches |
| Q37448116 | Cancer subclonal genetic architecture as a key to personalized medicine |
| Q35027361 | Chemoprevention of urothelial cell carcinoma growth and invasion by the dual COX-LOX inhibitor licofelone in UPII-SV40T transgenic mice |
| Q38718929 | Prevention and treatment of cancers by immune modulating nutrients. |
| Q36958356 | Simultaneous targeting of 5-LOX-COX and ODC block NNK-induced lung adenoma progression to adenocarcinoma in A/J mice |
| Q36820882 | Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo |
Search more.